Trials / Completed
CompletedNCT03140137
Immune Checkpoint Inhibitors and Pre-existing Autoimmune Diseases
Retrospective Observational Study on the Safety of Immune Checkpoint Inhibitors in the Treatment of Advanced Melanoma and Lung Cancers in Patients With Pre-Existing Autoimmune Diseases
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 112 (actual)
- Sponsor
- University Hospital, Brest · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The tolerance of immune checkpoint inhibitors is unknown in patients with pre-existing autoimmune conditions. This retrospective nation-wide study will assess their tolerance in patients with pre-existing autoimmune conditions who received immune checkpoint inhibitors for an advanced cancer in clinical practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Checkpoint inhibitor therapy | Treatment by ipilimumab, nivolumab or pembrolizumab for advanced cancer in clinical practice |
Timeline
- Start date
- 2017-01-21
- Primary completion
- 2018-01-04
- Completion
- 2018-01-04
- First posted
- 2017-05-04
- Last updated
- 2019-04-22
Locations
5 sites across 1 country: France
Source: ClinicalTrials.gov record NCT03140137. Inclusion in this directory is not an endorsement.